Security
Blade Air Mobility Inc. Warrants · BLDEW
BLDEWNASDAQWarrantHistorical · closed Aug 28, 2025CIK 1779128Updated Oct 3, 2026
Name history
Blade Air Mobility, Inc. · through Aug 18, 2025Experience Investment Corp. · through May 7, 2021
Current security for this SEC filerSRTA · NASDAQ
BLDEW price & chart
Historical security
This listing closed Aug 28, 2025. Live provider charts are shown only for current listings.
Current security: SRTA
About the company
Strata is a time-critical logistics and medical services provider to the U.S. healthcare industry. We operate one of the nation’s largest air transport and surgical services networks for transplant hospitals and organ procurement organizations, offering an integrated “one call” solution for donor organ recovery. Strata’s core services include air and ground logistics, surgical organ recovery, organ placement and normothermic regional perfusion for the transplant industry, as well as perfusion staffing and equipment solutions for cardiovascular surgery centers, offered under the Trinity Medical Solutions and Keystone Perfusion brands.
In the news
No coverage from other publishers is available.
Recent filings
144 filing
4 filing
4 filing
SCHEDULE 13G/A - filed by Steele ExpCo Holdings, LLC regarding Strata Critical Medical, Inc.
4 filing
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 325,472,000Source | 256,675,000Source | 294,938,000Source | 325,025,000Source |
| Property, Plant and Equipment, NetUSD | 36,444,000Source | 30,918,000Source | 2,899,000Source | 2,037,000Source |
| GoodwillUSD | 88,210,000Source | 41,050,000Source | 40,373,000Source | 39,445,000Source |
| Intangible Assets, Net (Excluding Goodwill)USD | 47,502,000Source | 13,653,000Source | 20,519,000Source | 46,365,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 30,968,000Source | 18,378,000Source | 27,873,000Source | 43,296,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 39,958,000Source | 21,591,000Source | 21,005,000Source | 10,877,000Source |
| Assets, CurrentUSD | 126,192,000Source | 160,742,000Source | 206,261,000Source | 218,126,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 24,739,000Source | 10,747,000Source | 17,971,000Source | 12,086,000Source |
| Operating Lease, Right-of-Use AssetUSD | 3,107,000Source | 8,876,000Source | 23,484,000Source | 17,692,000Source |
| Other Assets, NoncurrentUSD | 24,017,000Source | 1,436,000Source | 1,402,000Source | 970,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 46,400,000Source | 34,737,000Source | 60,638,000Source | 50,536,000Source |
| Stockholders’ equity: | ||||
| Preferred Stock, Value, IssuedUSD | 0Source | 0Source | 0Source | 0Source |
| Common Stock, Value, IssuedUSD | 7,000Source | 7,000Source | 7,000Source | 7,000Source |
| Additional Paid in CapitalUSD | 424,616,000Source | 407,076,000Source | 390,083,000Source | 375,873,000Source |
| Retained Earnings (Accumulated Deficit)USD | -145,551,000Source | -186,898,000Source | -159,754,000Source | -103,678,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 0Source | 1,753,000Source | 3,964,000Source | 2,287,000Source |
| Stockholders' Equity Attributable to ParentUSD | 279,072,000Source | 221,938,000Source | 234,300,000Source | 274,489,000Source |
| Liabilities and EquityUSD | 325,472,000Source | 256,675,000Source | 294,938,000Source | 325,025,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 19,794,000Source | 22,726,000Source | 35,491,000Source | 26,607,000Source |
| Operating Lease, Liability, CurrentUSD | 652,000Source | 3,304,000Source | 4,787,000Source | 3,362,000Source |
| Operating Lease, Liability, NoncurrentUSD | 2,655,000Source | 6,018,000Source | 19,738,000Source | 14,970,000Source |
| Deferred Income Tax Liabilities, NetUSD | 348,000Source | 185,000Source | 451,000Source | 1,876,000Source |
| Other Liabilities, NoncurrentUSD | 22,073,000Source | — | — | — |
| Additional Financial Items | ||||
| Deferred Tax Liabilities, NetUSD | 348,000Source | 185,000Source | 451,000Source | 1,876,000Source |
| Long-term DebtUSD | — | — | — | 0Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation, Depletion and AmortizationUSD | 8,185,000Source | 5,962,000Source | 7,111,000Source | 5,725,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 17,832,000Source | 19,893,000Source | 12,501,000Source | 8,277,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | 12,034,000Source | 998,000Source | 10,254,000Source | 5,347,000Source |
| Deferred Income Tax Expense (Benefit)USD | 432,000Source | -255,000Source | -1,466,000Source | -772,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -48,914,000Source | -2,519,000Source | -32,349,000Source | -37,130,000Source |
| Cash flows from investing activities: | ||||
| Payments to Acquire Businesses, Net of Cash AcquiredUSD | 66,535,000Source | 2,230,000Source | 0Source | 48,101,000Source |
| Net Cash Provided by (Used in) Investing ActivitiesUSD | 69,750,000Source | -1,016,000Source | 17,089,000Source | 79,340,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 9,595,000Source | 30,875,000Source | 2,109,000Source | 730,000Source |
| Cash flows from financing activities: | ||||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | 9,105,000Source | 5,683,000Source | 146,000Source | 1,171,000Source |
| Payments for Repurchase of Common StockUSD | 0Source | 244,000Source | — | — |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | -8,912,000Source | -5,759,000Source | -76,000Source | -1,084,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | 11,585,000Source | -9,374,000Source | -15,402,000Source | 41,198,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 31,232,000Source | 19,647,000Source | 29,021,000Source | 44,423,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | 0Source |
| Income Taxes Paid, NetUSD | 87,000Source | 0Source | 16,000Source | 0Source |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | -339,000Source | -80,000Source | -66,000Source | 72,000Source |
| Additional Financial Items | ||||
| Amortization of Intangible AssetsUSD | 2,604,000Source | 2,986,000Source | 6,036,000Source | 4,895,000Source |
| DepreciationUSD | 4,296,000Source | 2,976,000Source | 1,075,000Source | 830,000Source |
| Foreign Currency Transaction Gain (Loss), RealizedUSD | 798,000Source | — | — | — |
| Foreign Currency Transaction Gain (Loss), UnrealizedUSD | — | — | -6,000Source | -6,000Source |
| Gain (Loss) on Disposition of BusinessUSD | 56,996,000Source | — | — | — |
| Gain (Loss) on Sale of InvestmentsUSD | -5,195,000Source | 0Source | 8,000Source | -2,162,000Source |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | -2,073,000Source | — | -48,000Source | -68,000Source |
| General and Administrative ExpenseUSD | — | 81,711,000Source | 95,174,000Source | 62,510,000Source |
| GoodwillUSD | 88,210,000Source | 41,050,000Source | 40,373,000Source | 39,445,000Source |
| Impairment of Intangible Assets (Excluding Goodwill)USD | — | 5,759,000Source | — | — |
| Impairment of Intangible Assets, Finite-livedUSD | 0Source | — | — | — |
| Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)USD | — | 5,759,000Source | 20,753,000Source | — |
| Income (Loss) from Continuing Operations, Net of Tax, Attributable to ParentUSD | -20,066,000Source | — | — | — |
| Income (Loss) from Discontinued Operations, Net of Tax, Attributable to ParentUSD | 61,413,000Source | — | — | — |
| Income Tax Expense (Benefit)USD | 0Source | -255,000Source | -1,466,000Source | -772,000Source |
| Net Income (Loss) Attributable to ParentUSD | 41,347,000Source | -27,307,000Source | -56,076,000Source | -27,260,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | — | -27,260,000Source |
| Nonoperating Income (Expense)USD | 2,287,000Source | 6,364,000Source | 10,575,000Source | 25,497,000Source |
| Operating ExpensesUSD | 63,479,000Source | — | -33,226,000Source | -36,570,000Source |
| Other Nonoperating Income (Expense)USD | — | — | 10,575,000Source | 25,497,000Source |
| Proceeds from Stock Options ExercisedUSD | 193,000Source | 168,000Source | 70,000Source | 87,000Source |
| Restructuring CostsUSD | — | 1,441,000Source | — | — |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 197,141,000Source | 248,693,000Source | 225,180,000Source | 146,120,000Source |
| Cost of Goods and Services Sold | — | — | — | — |
| Selling, General and Administrative ExpenseUSD | 60,875,000Source | — | — | — |
| Operating Income (Loss)USD | -22,353,000Source | -33,926,000Source | -68,117,000Source | -53,529,000Source |
| Other Nonoperating Income (Expense)USD | — | — | 10,575,000Source | 25,497,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -20,066,000Source | -27,562,000Source | -57,542,000Source | -28,032,000Source |
| Income Tax Expense (Benefit)USD | 0Source | -255,000Source | -1,466,000Source | -772,000Source |
| Net Income (Loss) Attributable to ParentUSD | 41,347,000Source | -27,307,000Source | -56,076,000Source | -27,260,000Source |
| Earnings Per Share, BasicUSD per share | 0.5Source | -0.35Source | -0.76Source | -0.38Source |
| Earnings Per Share, DilutedUSD per share | 0.5Source | -0.35Source | -0.76Source | -0.38Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 82,092,345Source | 77,499,423Source | 73,524,476Source | 71,238,103Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 82,092,345Source | 77,499,423Source | 73,524,476Source | 71,238,103Source |
| Additional Financial Items | ||||
| Amortization of Intangible AssetsUSD | 2,604,000Source | 2,986,000Source | 6,036,000Source | 4,895,000Source |
| Business Combination, Acquisition Related CostsUSD | — | 241,000Source | — | — |
| Costs and ExpensesUSD | — | 282,619,000Source | 293,297,000Source | 199,649,000Source |
| Current Income Tax Expense (Benefit)USD | — | 0Source | 0Source | 0Source |
| Foreign Currency Transaction Gain (Loss), RealizedUSD | 798,000Source | — | — | — |
| General and Administrative ExpenseUSD | — | 81,711,000Source | 95,174,000Source | 62,510,000Source |
| Gross ProfitUSD | 41,126,000Source | — | — | — |
| Income (Loss) from Continuing Operations, Net of Tax, Attributable to ParentUSD | -20,066,000Source | — | — | — |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | -20,066,000Source | -14,859,000Source | -26,676,000Source | -21,563,000Source |
| Income (Loss) from Continuing Operations, Per Basic ShareUSD per share | -0.24Source | — | — | — |
| Income (Loss) from Continuing Operations, Per Diluted ShareUSD per share | -0.24Source | — | — | — |
| Income (Loss) from Discontinued Operations, Net of Tax, Attributable to ParentUSD | 61,413,000Source | — | — | — |
| Interest Income (Expense), NetUSD | — | 7,214,000Source | 8,442,000Source | 3,434,000Source |
| Interest Income (Expense), Nonoperating, NetUSD | 4,241,000Source | 7,214,000Source | — | — |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | — | -27,260,000Source |
| Nonoperating Income (Expense)USD | 2,287,000Source | 6,364,000Source | 10,575,000Source | 25,497,000Source |
| Operating ExpensesUSD | 63,479,000Source | — | -33,226,000Source | -36,570,000Source |
| Restructuring CostsUSD | — | 1,441,000Source | — | — |
| Selling and Marketing ExpenseUSD | — | 7,950,000Source | 10,438,000Source | 7,749,000Source |
| Undistributed Earnings (Loss) Allocated to Participating Securities, BasicUSD | — | — | — | 0Source |
Filing attachments
tm265039d1_ex99-1.htm · 8-K · 2026-02-05
EX-99.1 4 tm265039d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Strata Announces Closing of Revolving Credit Facility to Support Acquisition Strategy Execution $30 million ABL Facility will support future acquisitions and be undrawn at close; can be increased to $50 million, subject to certain conditions Owned aircraft excluded from collateral package and remain unencumbered New York, Feb 5, 2026 -- Strata Critical Medical, Inc. (Nasdaq: SRTA, “Strata” or the “Company”), a leading provide…
Read attachment ↗tm2532670d1_ex99-1.htm · 8-K · 2025-12-03
EX-99.1 2 tm2532670d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Strata Critical Medical, Inc. Appoints Will Cook to Board of Directors New York, New York December 3, 2025 -- The Board of Directors (the “Board”) of Strata Critical Medical, Inc. (“Strata” or the “Company”), a leading provider of logistics and medical services in the organ transplant industry, today announced the appointment of Will Cook to the Board, effective December 2, 2025. Mr. Cook has also been appointed to the Compensation…
Read attachment ↗tm2524340d2_ex99-1.htm · 8-K · 2025-08-29
EX-99.1 7 tm2524340d2_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 STRATA CRITICAL MEDICAL, INC. UNAUDITED PRO FORMA CONDENSED CONSOLIDATED FINANCIAL STATEMENTS Overview On August 29, 2025, Strata Critical Medical, Inc. (f/k/a Blade Air Mobility, Inc) (the “Company”) completed the previously announced sale of its Passenger business (the “Passenger Business Sale”) to Joby Aero, Inc., (the “Joby Buyer”) pursuant to that certain Equity Purchase Agreement, dated August 1, 2025 (the “Purchase Agreeme…
Read attachment ↗tm2524340d2_ex99-2.htm · 8-K · 2025-08-29
EX-99.2 8 tm2524340d2_ex99-2.htm EXHIBIT 99.2 Exhibit 99.2 Blade Completes Sale of Passenger Business and Planned Name Change to Strata Critical Medical, Begins Trading Under Ticker Symbol SRTA NEW YORK - (August 29, 2025) - Strata Critical Medical, Inc. (Nasdaq: SRTA, "Strata" or the "Company"), formerly known as Blade Air Mobility, Inc. (Nasdaq: BLDE), today announced the successful closing of the previously announced divestiture of the Company's Passenger business to Joby Aviation, Inc…
Read attachment ↗tm2522427d1_ex99-1.htm · 8-K · 2025-08-04
EX-99.1 4 tm2522427d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Blade announces sale of Passenger Division to Joby, Transitions to Pure-Play Medical Services and Logistics Business Blade Passenger division to be sold to Joby Aviation for up to $125 million Blade’s Medical division will remain public and rebrand as Strata post-close, focusing entirely on its rapidly growing contractual medical services and logistics business Long-term partnership between Joby and Strata will provide f…
Read attachment ↗